Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21 janv. 2025 09h15 HE
|
Dogwood Therapeutics, Inc.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid,...
Florida Oncology and Hematology Relocates Fort Myers Clinic
21 janv. 2025 08h00 HE
|
American Oncology Network
Florida Oncology and Hematology Relocates Fort Myers Clinic
Local oncology practice moves to a new location.
Allsup Supports Cervical Cancer Awareness Month With SSDI Expertise For Patients
16 janv. 2025 11h45 HE
|
Allsup
Belleville, Illinois, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Allsup, the nation’s leading provider of Social Security Disability Insurance (SSDI) representation services, is shining a light on Cervical...
University Cancer & Blood Center physicians recognized among Atlanta’s Top Doctors in Modern Luxury Medicine + Doctors magazine
15 janv. 2025 14h14 HE
|
University, Cancer and Blood Center
Four physicians from University Cancer & Blood Center are recognized as Top Doctors in Modern Luxury Medicine + Doctors magazine.
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
15 janv. 2025 09h05 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces –...
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
13 janv. 2025 08h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
13 janv. 2025 08h00 HE
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10 janv. 2025 10h21 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
07 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
07 janv. 2025 08h00 HE
|
Hummingbird Bioscience
Hummingbird Bioscience Licenses Novel Antibodies to Immunome